BBZA — BB Biotech AG Income Statement
0.000.00%
Last trade - 00:00- €2.60bn
- €335.04m
- CH₣616.74m
Annual income statement for BB Biotech AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | -344 | 1.26 | 0.53 | 112 | 617 |
| Cost of Revenue | |||||
| Gross Profit | -345 | -0.465 | -5.27 | 107 | 617 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 61.1 | 359 | 207 | 36.3 | 38.5 |
| Operating Profit | -405 | -358 | -207 | 76 | 578 |
| Net Income Before Taxes | -405 | -358 | -207 | 76 | 578 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -405 | -358 | -207 | 75.9 | 578 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -405 | -358 | -207 | 75.9 | 578 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -405 | -358 | -207 | 75.9 | 578 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.31 | -6.5 | -3.77 | 1.38 | 10.5 |
| Dividends per Share |